CervoMed Inc. (NASDAQ: CRVO) announced it has selected a 50mg three times daily dosing regimen of neflamapimod for its planned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE